Galectin Therapeutics is working to improve the lives of patients with NASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in NASH cirrhosis.
News
-
03/31/25
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update -
02/18/25
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial -
01/10/25
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (NASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More